Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

RANKL Blockade May Aid Breast Cancer Prevention in High-Risk Patients

DOI: 10.1158/2159-8290.CD-RW2016-125 Published August 2016
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: Inhibition of RANKL signaling may prevent breast tumorigenesis in BRCA1-mutation carriers.

  • Concept: In BRCA1-mutant breast tissue, RANK+ cells are highly proliferative and vulnerable to DNA damage.

  • Impact: RANKL inhibition has potential in breast cancer prevention therapy in patients with BRCA1 mutations.

Individuals who harbor germline mutations in the breast-cancer-susceptibility gene BRCA1 have an increased risk of developing breast cancer. The resulting tumors are often hormone receptor–negative basal-like tumors with deregulated progesterone signaling that have a poor prognosis. Patients carrying BRCA1 mutations often undergo prophylactic mastectomy to reduce the risk of breast cancer, and effective preventative therapies are needed. The receptor activator of nuclear factor kappa-B ligand (RANKL) is an important mediator of progesterone signaling in mammary gland development and tumorigenesis, prompting Nolan and colleagues to investigate the role of RANK–RANKL signaling in the initiation of breast tumorigenesis in patients carrying BRCA1 mutations. Breast tissue from normal, BRCA1-mutation, or BRCA2-mutation women revealed that RANK expression was restricted to normal luminal progenitor (LP) cells in wild-type and BRCA1-mutant breast tissue, with a larger fraction of RANK+ LP cells in BRCA1-mutant tissue, suggesting that enhanced RANK expression indicates a perturbed LP population in BRCA1-mutation carriers. RANK+ LP cells from BRCA1-mutation carriers exhibited increased clonogenic capacity and proliferation compared to RANK− cells and RANK+ cells from wild-type BRCA1 tissue. RANK+ LP cells exhibited enrichment of genes involved in cell cycle, proliferation, and DNA repair. Further, RANK+ progenitor cells from BRCA1-mutant tissue were more susceptible to DNA damage than RANK− progenitor cells. Data from The Cancer Genome Atlas revealed that RANK+ LP cells exhibited a basal-like gene signature, whereas RANK− cells were more similar to other subtypes, suggesting that RANK+ LP cells might be a target for breast cancer prevention therapy. The RANKL inhibitor, denosumab, blocked progesterone-induced proliferation in BRCA1-mutant organoids. Further, in a pilot window study, three BRCA1-mutation carriers treated with denosumab exhibited reduced breast epithelial cell proliferation. Finally, in BRCA1-deficient mouse models, RANKL inhibition resulted in delayed tumor onset. Altogether, these data imply that RANK signaling promotes tumorigenesis in BRCA1-mutation carriers, and suggest the potential for RANKL targeting in breast cancer prevention.

Nolan E, Vaillant F, Branstetter D, Pal B, Giner G, Whitehead L, et al. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med 2016 Jun 20 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (8)
August 2016
Volume 6, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
RANKL Blockade May Aid Breast Cancer Prevention in High-Risk Patients
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
RANKL Blockade May Aid Breast Cancer Prevention in High-Risk Patients
Cancer Discov August 1 2016 (6) (8) 816; DOI: 10.1158/2159-8290.CD-RW2016-125

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
RANKL Blockade May Aid Breast Cancer Prevention in High-Risk Patients
Cancer Discov August 1 2016 (6) (8) 816; DOI: 10.1158/2159-8290.CD-RW2016-125
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Cell-Intrinsic Programs Partition Nutrients in Tumor Microenvironment
  • Extrachromosomal DNA Can Promote Oncogene Transcription in Trans
  • Transient Rest Reverses Exhaustion of Chimeric Antigen Receptor T Cells
Show more Research Watch

Breast Cancer

  • Androgen Receptor Functions as a Tumor Suppressor in ER+ Breast Cancer
  • Immunosuppressive Macrophages Limit PARP Inhibitor Efficacy in TNBC
  • Imaging Can Identify PI3Kα-Inhibitor Susceptibility in Breast Cancer
Show more Breast Cancer
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement